Articles tagged with: IMW 2011
News»
Thursday was the third day of the International Myeloma Workshop (IMW) in Paris. There were presentations from early morning through the evening.
Some of the highlights from the first part of Day 3 of the conference are summarized in this article. Highlights from the second part of the day are summarized in a separate article (see related Beacon news).
Treating Older, Newly Diagnosed Myeloma Patients
The first session of the morning was about treating newly diagnosed multiple myeloma patients over the age of 65 years, specifically those who are ineligible for …
News»
In a session of the International Myeloma Workshop (IMW) today, multiple myeloma experts presented the latest data about the efficacy of Revlimid maintenance therapy and discussed the drug’s potential link to second cancers.
Results from a study conducted by the Cancer and Leukemia Group B (CALGB) showed that Revlimid (lenalidomide) maintenance therapy following stem cell transplantation significantly extends survival of myeloma patients. Two other studies investigating Revlimid maintenance, the IFM 2005-02 and MM-015 studies, have not yet shown a survival benefit.
All three studies, however, have raised concerns that Revlimid maintenance …
News»
Yesterday was the second day of the International Myeloma Workshop (IMW) in Paris. The day was full of presentations from early morning through the evening, and the day concluded with a poster session.
Some of the highlights from Day 2 of the conference are summarized in this article. For more detailed summaries of the day's sessions, see The Beacon’s extensive Day 2 coverage in the Beacon Forums.
Treating Younger, Newly Diagnosed Myeloma Patients
The first session of the morning was about treating newly diagnosed patients under the age of 65 years.
First, Dr. …
News»
This year’s International Myeloma Workshop (IMW) started in Paris yesterday morning and will continue through Friday.
Yesterday’s schedule included three sessions of oral presentations and a poster session in the afternoon. The focus of the oral sessions was to present the current understanding of the biochemistry and molecular mechanisms related to multiple myeloma.
These talks were more technical than the ones that will be made later in the week, and their material will not likely have an immediate impact on how current multiple myeloma patients are treated.
In particular, yesterday’s sessions included …
NewsFlash »
Millennium And Takeda Apply For FDA Approval Of Subcutaneous Velcade – Millennium and Takeda, the companies that market Velcade, have submitted an application to the Food and Drug Administration (FDA) for approval of Velcade (bortezomib) to be administered subcutaneously (injected into the fat just below the skin). Currently, Velcade is approved to be administered intravenously. Recent results have shown that subcutaneous Velcade is as effective as IV Velcade, but subcutaneous administration reduces the frequency and seriousness of side effects. In particular, the rate of peripheral neuropathy (pain and tingling in the extremities) dropped from 16 percent to 6 percent. Additionally, many patients may consider subcutaneous injections more convenient because they can be administered from home. For more information, see the Millennium press release or the Beacon’s coverage of the results comparing the efficacy and side effects of the two routes of administration.
Highlights From The 13th International Myeloma Workshop – The 13th International Myeloma Workshop will be held in Paris tomorrow through Friday. Staff from The Myeloma Beacon will be attending and reporting live from the meeting. The Beacon’s coverage will include brief “as it happens” summaries of presentations to be posted to the Beacon forums as well as daily update articles that summarize the day’s events and key presentations. Discussion threads have been created in the forums for each day of the meeting (Day 1, Day 2, Day 3, and Day 4). All Beacon readers are welcome to participate in the discussions. The Beacon’s coverage of the Workshop is made possible in part by financial support from the Tackle Cancer Foundation.
After the conclusion of the Workshop, the Multiple Myeloma Research Foundation (MMRF) will sponsor a teleconference for patients and caregivers in which myeloma specialists will present highlights from the meeting. Dr. Thierry Facon from the University of Lille in France as well as Dr. Paul Richardson from the Dana-Farber Cancer Institute will present the latest advances in myeloma treatment. Their presentation will be followed by a question and answer session. The call will take place on May 6 from noon till 1 p.m. Eastern time. For more information or to register, see the MMRF event website.
Multiple Myeloma Education Programs – Two educational programs for multiple myeloma patients will be held on May 14. Dr. Jeff Wolf will speak at the event held in San Jose, CA, and Dr. Ronjay Rakkit will speak at the event in Houston. The physicians will also answer patients’ questions. In addition, a multiple myeloma patient will speak at each program. Attendees can also connect with others at the event who have been affected by myeloma. Both events are sponsored by Millennium. For more information, see the Beacon event descriptions (San Jose, Houston). To register, call 1-866-508-6181.
News»
The 13th International Myeloma Workshop will take place Tuesday, May 3, through Friday, May 6, in Paris. During the four-day meeting, multiple myeloma specialists from all over the world will discuss the current understanding of the biology and treatment of myeloma.
Additionally, much awaited data about the safety and effectiveness of Revlimid (lenalidomide) maintenance therapy will be presented at the meeting.
The Myeloma Beacon will be covering the event, so readers can expect many articles during the meeting and in the weeks afterward about the key myeloma findings.
The International Myeloma …
